explore -WSS

explore

author：hotspot 2025-09-28 00:47:51 - browse：577

Nick Leschly - Bluebird Bio — Longtime Bluebird Bio CEO Nick Leschly Wendy Maeda/The Boston Globe

Some two years after splitting biotech company Bluebird Bio into two entities in a bid to “sharpen their focus” and improve operations, the spinout focused on oncology treatments announced major cost cuts and is parting ways with its chief executive.

The spinout, 2Seventy Bio, announced Tuesday that it is cutting approximately 40% of its workforce, or about 176 employees. It also plans to allocate less money to a couple of drug candidates, including one that is currently on hold with the Food and Drug Administration. The cuts extend the company’s cash runway into 2026.

The company was formed in 2021 when the team behind Bluebird Bio decided to split its drug pipeline down the middle. The company was wrestling with its gene therapy portfolio, including getting approval for a gene therapy for the blood disorder beta thalassemia in the U.S. Separately, it had a basket of cancer drug candidates and a partnership with pharma company Bristol Myers Squibb that needed attention. So, Bluebird split its operations in two, with longtime CEO Nick Leschly taking the helm at the new firm.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

WSS

Global cancer cases to surge 77% by 2050, WHO report says

Trader Joe's recalls 10K cases of broccoli cheddar soup over potential foreign material

Moscow blames Kyiv for missile attacks in southern Russia as Kremlin forces pound Ukrainian village

Readout LOUD: Venture capital, Gilead, and more M&A

Devoted Health’s losses in Medicare Advantage persist

Adopting new red light myopia treatments may be short

knowledge

explore

hotspot

Hollywood unions extend contract negotiations for actors

Padmanee Sharma of MD Anderson at center of lawsuit over credit

23andMe had bad news about my health. I wish a person had delivered it

AI gets buy

Activists slam private health insurers over coverage restrictions

Stoke drug shows lower activity against childhood epilepsy

ChatGPT in medicine: STAT answers readers' burning questions

An outrageous hospital charge: I paid $710 for an hour of babysitting

DIEP, the 'gold standard' of breast reconstruction, is under threat

Moscow blames Kyiv for missile attacks in southern Russia as Kremlin forces pound Ukrainian village

focus

As the dark side of IVF slowly comes into focus, even more transparency is needed

Updated Covid vaccine has 54% effectiveness, new study suggests

Trump allegedly attempted to have surveillance video deleted: Special Counsel

Medicare Advantage plans can’t deny care with AI, CMS warns

Cano Health’s bankruptcy is a warning for Medicare Advantage

Ford recalls 870K F

focus

knowledge

focus

focus